Craft

Third Harmonic Bio

Stock Price

$14.6

2024-10-29

Market Capitalization

$599.2 M

2024-10-29

Third Harmonic Bio Summary

Company Summary

Overview
Third Harmonic Bio is a clinical-stage biopharmaceutical company focused on the development of medicine for the treatment of allergic and inflammatory diseases. Its lead product candidate, THB001, is an oral small molecule inhibitor of KIT, a cell surface receptor that acts as the master survival and functional regulator of mast cells.
Type
Public
Status
Active
Founded
2019
HQ
Cambridge, MA, US | view all locations
Website
https://thirdharmonicbio.com/
Cybersecurity rating
Sectors

Key People

  • Natalie Holles

    Natalie Holles, Chief Executive Officer

  • Robert Ho

    Robert Ho, Chief Financial Officer

  • Adrian S. Ray

    Adrian S. Ray, Chief Scientific Officer

  • David Bonita, Director

    LocationsView all

    1 location detected

    • Cambridge, MA HQ

      United States

      300 Technology Square 8th Floor

    Third Harmonic Bio Financials

    Summary Financials

    Net income (Q1, 2025)
    ($15.8M)
    Cash (Q1, 2025)
    $271.6M
    EBIT (Q1, 2025)
    ($18.7M)
    Enterprise value
    $330.6M

    Footer menu